Drug · DIN 02498316
RIXIMYO
SINGLE-USE VIALS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 22, 2020; first marketed May 22, 2020.
- Drug Identification Number (DIN)
- 02498316
- Company (DIN owner)
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Rituximab L01FA01
- Class
- Human
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RITUXIMAB | 10 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 28, 2020: NOC 23519New Drug Submission (NDS)